Greg's Alzheimer's Research Report

Greg's Alzheimer's Research Report

Part 63 - Lecanemab vs. Donanemab

January 6, 2026

Greg Rowland's avatar
Greg Rowland
Jun 08, 2026
∙ Paid

Today, I received my seventh infusion of Lecanemab. In the space next to me was a woman receiving her first infusion of Donanemab. (the infusion chairs are separated by curtains for visual privacy; however, there is no voice privacy).

After a three-hour nap when I arrived at home after my infusion, I became curious about the difference between Lecanemab and Donanemab. Before I started my infusions, I learned a bit about the differences of these two medications. At that point, I was a newbie to the world of Alzheimer’s. I recall writing in an early blog post that I was “scared shitless.” Fast-forward three and a half months and I consider myself a well-informed, untrained, amateur Alzheimer’s patient and seeker of information. In other words, I know a thing or two about Alzheimer’s disease.

Let’s take a moderately deep dive into Lecanemab and Donanemab.

User's avatar

Continue reading this post for free, courtesy of Greg Rowland.

Or purchase a paid subscription.
© 2026 Rowjera Holdings Inc · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture